Skip to main content

Prelude Therapeutics Inc 10-Q for FY2026 Q3

Prelude Therapeutics Inc (PRLD)

10-Q 2026-11-16 For: 2026-09-30
View Original
Added on November 16, 2026

About this 10-Q

Prelude Therapeutics Inc filed this 10-Q on November 16, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Prelude began Phase 1 enrollment for PRT13722 after September 2026 FDA clearance and entered an October 2026 clinical trial collaboration with Eli Lilly and Company to evaluate abemaciclib and imlunestrant combinations in HR+/HER2- breast cancer. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$5.65M
down 13.1% from $6.5M a year earlier
Net loss
$12.54M
compared with a net loss of $19.73M a year earlier
Diluted EPS
-$0.12
compared with -$0.26 a year earlier